NASDAQ: PDSB · Life Sciences · 8 alerts · CIK 1472091
Share price
$0.9241Close, Nov 16
Market cap
$97M
Shares outstanding
105.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PDS Biotechnology Corp filings on SEC EDGAR ↗
NantWorks exercised outstanding common stock warrants to purchase 17,699,115 shares of PDS Biotechnology at an exercise price of $0.22 per share. The transaction generated approximately $3.9 million in gross proceeds for the company. PDS Biotech intends to use the funds to advance its PDS0301 program toward a Phase 3 trial in metastatic colorectal cancer and for general corporate purposes.
PDS Biotechnology completed the initial closing of a PIPE financing led by Nant Capital, raising $11.3 million in gross proceeds through the sale of common stock and warrants. The company also announced a contingent milestone closing for an additional $11 million and appointed Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. Proceeds will be used to repay $4.6 million in debt to Yorkville and advance the PDS0301 clinical program.